title: The role and mechanism of autophagy in sorafenib targeted cancer therapy.
abstract: Targeting kinase inhibitors (TKIs) are effective tools for treating advanced cancer. However, acquired resistance represents a roadblock in the use of TKIs, such as sorafenib, for cancer therapy. Understanding the acquisition of resistance to sorafenib will help doctors to cope with acquired resistance to TKIs in general and to develop personalized medicine strategies for cancer patients. Autophagy is a biological process that occurs in normal organisms. However, it is also a component of multiple disease processes, including cancer development and progression. However, the roles of autophagy in cancer and in response to cancer therapy are controversial. In this review, we summarize the progress in autophagy and sorafenib resistance research, which is representative of acquired resistance to targeted cancer therapy.
authors.affiliation: Department of Nuclear Medicine, Zhejiang Cancer Hospital, 38 Guangji Road, Hangzhou, Zhejiang Province 310021, PR China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Heqing
authors.affiliation: Department of Nuclear Medicine, Zhejiang Cancer Hospital, 38 Guangji Road, Hangzhou, Zhejiang Province 310021, PR China.
authors.forename: Long
authors.initials: L
authors.lastname: Bin
authors.affiliation: Department of Nuclear Medicine, Zhejiang Cancer Hospital, 38 Guangji Road, Hangzhou, Zhejiang Province 310021, PR China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Xuemei
authors.affiliation: Department of Nuclear Medicine, Zhejiang Cancer Hospital, 38 Guangji Road, Hangzhou, Zhejiang Province 310021, PR China. Electronic address: pet-ct001@163.com.
authors.forename: Li
authors.initials: L
authors.lastname: Linfa
mesh_terms: D000818:Animals; D001343:Autophagy / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000379:methods*; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib
keywords: Acquired resistance; Autophagy; Sorafenib; Targeting kinase inhibitor